INS-VAGINAL ESTROGEN COVERAGE House SponsorsRep. Katie Stuart-Ann M. Williams, Nicholas K. Smith, Anna Moeller, Terra Costa Howard, Jonathan Carroll, LaToya Greenwood, Deb Conroy, Robyn Gabel, Barbara Hernandez, Mark L. Walker, Dagmara Avelar, Rita Mayfield, Maurice A. West, II, Sue Scherer, Natalie A. Manley, Janet Yang Rohr, Camille Y. Lilly, Jehan Gordon-Booth and Suzanne Ness Senate Sponsors(Sen. Meg Loughran Cappel-Rachelle Crowe and Jacqueline Y. Collins) 1/10/2023HouseSession Sine Die 5 ILCS 375/6.1155 ILCS 5/5-1069.365 ILCS 5/10-4-2.3105 ILCS 5/10-22.3f215 ILCS 5/356z.53 new215 ILCS 125/5-3from Ch. 111 1/2, par. 1411.2215 ILCS 130/4003from Ch. 73, par. 1504-3215 ILCS 165/10from Ch. 32, par. 604305 ILCS 5/5-16.8 Amends the Illinois Insurance Code. Provides that a group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed on or after January 1, 2024 and that provides coverage for prescription drugs shall provide coverage for vaginal estrogen, and that coverage for vaginal estrogen shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement. Makes conforming changes in the State Employees Group Insurance Act of 1971, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, the Voluntary Health Services Plans Act, and the Medical Assistance Article of the Illinois Public Aid Code.House Committee Amendment No. 1 Replaces everything after the enacting clause with the provisions of the introduced bill with the following changes. Provides that a group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed on or after January 1, 2024 and that provides coverage for prescription drugs shall include coverage for one or more therapeutic equivalent versions of vaginal estrogen in its formulary (rather than provide coverage for vaginal estrogen), and that a policy is not required to include all therapeutic equivalent versions of vaginal estrogen in its formulary so long as at least one is included and covered without cost sharing and in accordance with the provisions. Provides that if an individual's attending provider recommends a particular vaginal estrogen product or its therapeutic equivalent version approved by the United States Food and Drug Administration based on the provider's determination, the issuer must cover that service or item without cost sharing. Provides that coverage for vaginal estrogen shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided, except to the extent such coverage would disqualify a high-deductible health plan from eligibility for a health savings account pursuant to specified federal law. Defines "therapeutic equivalent version". 1/4/2022HouseFiled with the Clerk by Rep. Katie Stuart 1/5/2022HouseFirst Reading 1/5/2022HouseReferred to Rules Committee 1/25/2022HouseAssigned to Insurance Committee 2/7/2022HouseAdded Co-Sponsor Rep. Nicholas K. Smith 2/7/2022HouseAdded Co-Sponsor Rep. Ann M. Williams 2/7/2022HouseAdded Co-Sponsor Rep. Anna Moeller 2/7/2022HouseAdded Co-Sponsor Rep. Terra Costa Howard 2/7/2022HouseAdded Co-Sponsor Rep. Jonathan Carroll 2/7/2022HouseRemoved Co-Sponsor Rep. Ann M. Williams 2/9/2022HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Katie Stuart 2/9/2022HouseHouse Committee Amendment No. 1 Referred to Rules Committee 2/14/2022HouseAdded Co-Sponsor Rep. LaToya Greenwood 2/15/2022HouseHouse Committee Amendment No. 1 Rules Refers to Insurance Committee 2/15/2022HouseHouse Committee Amendment No. 1 Adopted in Insurance Committee; by Voice Vote 2/15/2022HouseDo Pass as Amended / Consent Calendar Insurance Committee; 016-000-000 2/15/2022HouseAdded Co-Sponsor Rep. Deb Conroy 2/16/2022HousePlaced on Calendar 2nd Reading - Consent Calendar 2/17/2022HouseAdded Co-Sponsor Rep. Robyn Gabel 2/17/2022HouseAdded Co-Sponsor Rep. Barbara Hernandez 2/17/2022HouseAdded Chief Co-Sponsor Rep. Ann M. Williams 2/17/2022HouseSecond Reading - Consent Calendar 2/17/2022HouseHeld on Calendar Order of Second Reading - Consent Calendar 2/25/2022HouseAdded Co-Sponsor Rep. Mark L. Walker 2/28/2022HouseAdded Co-Sponsor Rep. Dagmara Avelar 2/28/2022HouseAdded Co-Sponsor Rep. Rita Mayfield 2/28/2022HouseAdded Co-Sponsor Rep. Maurice A. West, II 3/1/2022HouseAdded Co-Sponsor Rep. Sue Scherer 3/1/2022HousePlaced on Calendar Order of 3rd Reading - Consent Calendar 3/2/2022HouseAdded Co-Sponsor Rep. Natalie A. Manley 3/2/2022HouseThird Reading - Consent Calendar - First Day 3/3/2022HouseAdded Co-Sponsor Rep. Janet Yang Rohr 3/3/2022HouseAdded Co-Sponsor Rep. Camille Y. Lilly 3/3/2022HouseAdded Co-Sponsor Rep. Jehan Gordon-Booth 3/3/2022HouseAdded Co-Sponsor Rep. Suzanne Ness 3/3/2022HouseThird Reading - Consent Calendar - Passed 104-000-000 3/4/2022SenateArrive in Senate 3/4/2022SenatePlaced on Calendar Order of First Reading 3/7/2022SenateChief Senate Sponsor Sen. Rachelle Crowe 3/7/2022SenateFirst Reading 3/7/2022SenateReferred to Assignments 3/16/2022SenateAssigned to Insurance 3/25/2022SenateRule 2-10 Committee Deadline Established As April 4, 2022 3/31/2022SenateAlternate Chief Sponsor Changed to Sen. Meg Loughran Cappel 3/31/2022SenateAdded as Alternate Chief Co-Sponsor Sen. Rachelle Crowe 4/1/2022SenateRule 2-10 Third Reading Deadline Established As April 8, 2022 4/22/2022SenateAdded as Alternate Co-Sponsor Sen. Jacqueline Y. Collins 5/10/2022SenatePursuant to Senate Rule 3-9(b) / Referred to Assignments 1/10/2023HouseSession Sine Die